SCHEMBL699716

SCHEMBL699716

COc1c(C(=O)Cl)cccc1C(=O)Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
ALOX15 P16050 1/20 0.45
CTSD P07339 1/20 0.41
APEX1 P27695 4/20 0.41
CNR2 P34972 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
TP53 P04637 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7666396 0.90 ALDH1A1 (0.49) ALDH1A1ALOX15KDM4EHSD17B10NPC1
SCHEMBL31074983 0.88 NPC1 (0.53) ALDH1A1CTSDCNR2KDM4EHSD17B10
SCHEMBL5011915 0.88 ALDH1A1 (0.47) ALDH1A1ALOX15APEX1KDM4EHSD17B10
SCHEMBL341330 0.88 NPC1 (0.53) ALDH1A1CTSDCNR2KDM4EHSD17B10
SCHEMBL29472144 0.86 ALDH1A1 (0.38) ALDH1A1ALOX15CTSDAPEX1CNR2
SCHEMBL14431277 0.86 ALDH1A1 (0.47) ALDH1A1ALOX15CTSDKDM4EHSD17B10
SCHEMBL1515828 0.86 HSD17B10 (0.43) ALDH1A1ALOX15CTSDKDM4EHSD17B10
SCHEMBL24916 0.86 ALDH1A1 (0.57) ALDH1A1ALOX15KDM4ENPC1RAB9A
SCHEMBL15778308 0.86 ALDH1A1 (0.38) ALDH1A1ALOX15CTSDAPEX1CNR2
SCHEMBL29997568 0.86 TDP1 (0.44) ALDH1A1ALOX15CTSDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060332-B2 Liquid crystal display with alignment film of polyphenylenphthalamide-based material and method for fabricating the same LG.PHILIPS LCD CO., LTD. (KR) 2006-06-13 US claimed
US-20020182346-A1 Liquid crystal display with alignment film of polyphenylenphthalamide-based material and method for fabricating the same LG DISPLAY CO., LTD. (KR) 2002-12-05 US claimed
EP-2051968-B1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES UNIV CALIFORNIA (US) 2020-04-29 EP disclosed
EP-2051968-B1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES UNIV CALIFORNIA (US) 2020-04-29 EP disclosed
EP-3568398-A1 CRYPTATE DERIVATIVES AND THEIR USE AS LUMINESCENT LANTHANIDE COMPLEXES Société des Produits Nestlé S.A. (CH) 2019-11-20 EP disclosed
US-20190284211-A1 CRYPTATES AND METHODS OF USE NESTEC S.A. (CH) 2019-09-19 US disclosed
US-20190284211-A1 CRYPTATES AND METHODS OF USE NESTEC S.A. (CH) 2019-09-19 US disclosed
WO-2018130988-A1 CRYPTATE DERIVATIVES AND THEIR USE AS LUMINESCENT LANTHANIDE COMPLEXES NESTEC S.A. (CH) 2018-07-19 WO disclosed
EP-2423201-B1 Luminescent macrocyclic lanthanide complexes UNIV CALIFORNIA (US) 2017-10-04 EP disclosed
EP-2423201-B1 Luminescent macrocyclic lanthanide complexes UNIV CALIFORNIA (US) 2017-10-04 EP disclosed
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
WO-2008063721-A2 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-29 WO disclosed
WO-2008063721-A2 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-29 WO disclosed
US-7060332-B2 Liquid crystal display with alignment film of polyphenylenphthalamide-based material and method for fabricating the same LG.PHILIPS LCD CO., LTD. (KR) 2006-06-13 US disclosed
EP-1100486-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-01-15 EP disclosed
US-20020182346-A1 Liquid crystal display with alignment film of polyphenylenphthalamide-based material and method for fabricating the same LG DISPLAY CO., LTD. (KR) 2002-12-05 US disclosed
EP-1100486-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2001-05-23 EP disclosed
WO-2000006147-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 WO disclosed
US-4413114-A FOR FILMS OR FIBERS TEIJIN LIMITED (JP) 1983-11-01 US disclosed
US-4355151-A Aromatic copolyamide containing 3,4'-diamino diphenylene moiety TEIJIN LIMITED (JP) 1982-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284211-A1 CRYPTATES AND METHODS OF USE CA13, KLK3, ALPG ALDH1A1 598/4885ALOX15 3859/4885CTSD 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.